Iraqi Registry Data Proves Safety and Efficacy of switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis
Background: Adalimumab is approved for Rheumatoid Arthritis (RA). In 2021, A biosimilar (ABP501;Amgevita®) was licensed in Iraq. The current study aimed to ensure safety and Efficacy of Amgevita in RA Patients in Iraq. Patients and Methods: A Cross sectional Observational study Started on 69...
Saved in:
| Main Authors: | , , , , , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
University of Baghdad/ Al-Kindy College of Medicine
2024-12-01
|
| Series: | مجله كليه طب الكندي |
| Subjects: | |
| Online Access: | https://jkmc.uobaghdad.edu.iq/index.php/MEDICAL/article/view/1476 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
| _version_ | 1850175491972005888 |
|---|---|
| author | Yasameen Abbas Nabaa Ihsan Asal Adnan Marwa Moayad Ali AlKazzaz Avin Maroof Ali Abdulrahman Nazar Abdulateef Mohammad AlOsami Faiq Gorial Mohammed Altahhan Zahraa Almansi Ali Alnoori |
| author_facet | Yasameen Abbas Nabaa Ihsan Asal Adnan Marwa Moayad Ali AlKazzaz Avin Maroof Ali Abdulrahman Nazar Abdulateef Mohammad AlOsami Faiq Gorial Mohammed Altahhan Zahraa Almansi Ali Alnoori |
| author_sort | Yasameen Abbas |
| collection | DOAJ |
| description |
Background: Adalimumab is approved for Rheumatoid Arthritis (RA). In 2021, A biosimilar (ABP501;Amgevita®) was licensed in Iraq. The current study aimed to ensure safety and Efficacy of Amgevita in RA Patients in Iraq.
Patients and Methods: A Cross sectional Observational study Started on 69 RA Records receiving Amgevita. Data collected from local registry then examined for disease activity and adverse reactions for 9 months follow up.
Results: Thirty patients completed the 9 months period of the study: aged (49±14) years; 77.5% females. After 3, 6 and 9 months of follow up, patients' mean (SD) CDAI 27.8 ( 13.60 ) which was statistically lower (19.80) (6.96), 17.70 (2.790), and 19 (1.040), p<0.001. With a mean change of CDAI: 8 (p<0.001), 10.1 (p<0.001), and 8.78 (p<0.001) after 3, 6, and 9 months. Cumulative percentage of responders was 55.00% and Cumulative percentage of probability of change of disease activity was 86.00%, No patient achieved remission and no significant Side effects recorded. In conclusion Amgevita is Effective and Safe in RA.
|
| format | Article |
| id | doaj-art-d68a3c4d49804f399e2dca9d7ec83d43 |
| institution | OA Journals |
| issn | 1810-9543 2521-4365 |
| language | English |
| publishDate | 2024-12-01 |
| publisher | University of Baghdad/ Al-Kindy College of Medicine |
| record_format | Article |
| series | مجله كليه طب الكندي |
| spelling | doaj-art-d68a3c4d49804f399e2dca9d7ec83d432025-08-20T02:19:27ZengUniversity of Baghdad/ Al-Kindy College of Medicineمجله كليه طب الكندي1810-95432521-43652024-12-0120310.47723/2km3dk271402Iraqi Registry Data Proves Safety and Efficacy of switching to Adalimumab Biosimilar in Treating Rheumatoid ArthritisYasameen Abbas0Nabaa Ihsan1https://orcid.org/0000-0002-7634-0146Asal Adnan2https://orcid.org/0000-0001-9140-5860Marwa Moayad3https://orcid.org/0000-0001-5686-6311Ali AlKazzaz4https://orcid.org/0000-0002-7852-1581Avin Maroof5https://orcid.org/0000-0002-6554-5314Ali Abdulrahman 6https://orcid.org/0000-0003-4561-8528Nazar Abdulateef7https://orcid.org/0000-0003-0659-8130Mohammad AlOsami8https://orcid.org/0000-0001-8521-5876Faiq Gorial9https://orcid.org/0000-0002-2760-5566Mohammed Altahhan10https://orcid.org/0000-0002-8507-8303Zahraa Almansi11https://orcid.org/0000-0002-2784-4815Ali Alnoori12https://orcid.org/0000-0002-0551-7725Department of Internal Medicine, Al-Nahrain University, College of Medicine, Baghdad, IraqDepartment of Internal Medicine, University of Baghdad, Baghdad, IraqRheumatology Consultation Clinic, Medical City, Baghdad, IraqRheumatology Consultation Clinic, Al-Yarmouk Hospital, Baghdad, IraqDepartment of Internal Medicine, Babylon University, Hilla, IraqDepartment of Internal Medicine, School of medicine-University of Kurdistan Hawlêr, IraqDepartment of Internal Medicine, University of Mosul, Mosul, IraqRheumatology Consultation Clinic, Medical City, Baghdad, IraqRheumatology Consultation Clinic, Medical City, Baghdad, IraqRheumatology Consultation Clinic, Medical City, Baghdad, IraqDepartment of Internal Medicine, University of Baghdad, Baghdad, IraqDepartment of Internal Medicine, University of Baghdad, Baghdad, IraqDepartment of Internal Medicine, University of Baghdad, Baghdad, Iraq Background: Adalimumab is approved for Rheumatoid Arthritis (RA). In 2021, A biosimilar (ABP501;Amgevita®) was licensed in Iraq. The current study aimed to ensure safety and Efficacy of Amgevita in RA Patients in Iraq. Patients and Methods: A Cross sectional Observational study Started on 69 RA Records receiving Amgevita. Data collected from local registry then examined for disease activity and adverse reactions for 9 months follow up. Results: Thirty patients completed the 9 months period of the study: aged (49±14) years; 77.5% females. After 3, 6 and 9 months of follow up, patients' mean (SD) CDAI 27.8 ( 13.60 ) which was statistically lower (19.80) (6.96), 17.70 (2.790), and 19 (1.040), p<0.001. With a mean change of CDAI: 8 (p<0.001), 10.1 (p<0.001), and 8.78 (p<0.001) after 3, 6, and 9 months. Cumulative percentage of responders was 55.00% and Cumulative percentage of probability of change of disease activity was 86.00%, No patient achieved remission and no significant Side effects recorded. In conclusion Amgevita is Effective and Safe in RA. https://jkmc.uobaghdad.edu.iq/index.php/MEDICAL/article/view/1476Rheumatoid arthritisBiosimilarAdalimumab |
| spellingShingle | Yasameen Abbas Nabaa Ihsan Asal Adnan Marwa Moayad Ali AlKazzaz Avin Maroof Ali Abdulrahman Nazar Abdulateef Mohammad AlOsami Faiq Gorial Mohammed Altahhan Zahraa Almansi Ali Alnoori Iraqi Registry Data Proves Safety and Efficacy of switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis مجله كليه طب الكندي Rheumatoid arthritis Biosimilar Adalimumab |
| title | Iraqi Registry Data Proves Safety and Efficacy of switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis |
| title_full | Iraqi Registry Data Proves Safety and Efficacy of switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis |
| title_fullStr | Iraqi Registry Data Proves Safety and Efficacy of switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis |
| title_full_unstemmed | Iraqi Registry Data Proves Safety and Efficacy of switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis |
| title_short | Iraqi Registry Data Proves Safety and Efficacy of switching to Adalimumab Biosimilar in Treating Rheumatoid Arthritis |
| title_sort | iraqi registry data proves safety and efficacy of switching to adalimumab biosimilar in treating rheumatoid arthritis |
| topic | Rheumatoid arthritis Biosimilar Adalimumab |
| url | https://jkmc.uobaghdad.edu.iq/index.php/MEDICAL/article/view/1476 |
| work_keys_str_mv | AT yasameenabbas iraqiregistrydataprovessafetyandefficacyofswitchingtoadalimumabbiosimilarintreatingrheumatoidarthritis AT nabaaihsan iraqiregistrydataprovessafetyandefficacyofswitchingtoadalimumabbiosimilarintreatingrheumatoidarthritis AT asaladnan iraqiregistrydataprovessafetyandefficacyofswitchingtoadalimumabbiosimilarintreatingrheumatoidarthritis AT marwamoayad iraqiregistrydataprovessafetyandefficacyofswitchingtoadalimumabbiosimilarintreatingrheumatoidarthritis AT alialkazzaz iraqiregistrydataprovessafetyandefficacyofswitchingtoadalimumabbiosimilarintreatingrheumatoidarthritis AT avinmaroof iraqiregistrydataprovessafetyandefficacyofswitchingtoadalimumabbiosimilarintreatingrheumatoidarthritis AT aliabdulrahman iraqiregistrydataprovessafetyandefficacyofswitchingtoadalimumabbiosimilarintreatingrheumatoidarthritis AT nazarabdulateef iraqiregistrydataprovessafetyandefficacyofswitchingtoadalimumabbiosimilarintreatingrheumatoidarthritis AT mohammadalosami iraqiregistrydataprovessafetyandefficacyofswitchingtoadalimumabbiosimilarintreatingrheumatoidarthritis AT faiqgorial iraqiregistrydataprovessafetyandefficacyofswitchingtoadalimumabbiosimilarintreatingrheumatoidarthritis AT mohammedaltahhan iraqiregistrydataprovessafetyandefficacyofswitchingtoadalimumabbiosimilarintreatingrheumatoidarthritis AT zahraaalmansi iraqiregistrydataprovessafetyandefficacyofswitchingtoadalimumabbiosimilarintreatingrheumatoidarthritis AT alialnoori iraqiregistrydataprovessafetyandefficacyofswitchingtoadalimumabbiosimilarintreatingrheumatoidarthritis |